{"id":157491,"date":"2017-11-02T15:42:03","date_gmt":"2017-11-02T15:42:03","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=157491"},"modified":"2017-11-02T15:42:03","modified_gmt":"2017-11-02T15:42:03","slug":"monoclonal-antibodies-market-segmentation-by-regions-production-consumption-and-revenue-20172022","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/monoclonal-antibodies-market-segmentation-by-regions-production-consumption-and-revenue-20172022_157491.html","title":{"rendered":"Monoclonal Antibodies Market Segmentation by Regions, Production, Consumption and Revenue 2017-2022"},"content":{"rendered":"
\"\"<\/a><\/div>\n
Reports Web announces the release of market assessment report on \u201cMonoclonal Antibodies-Global Trends in the Competitive, Technological and R&D Landscape”. The report is segmented into several key Regions, with production, consumption, revenue and market share.<\/div>\n

GBI Research’s latest report, “Monoclonal Antibodies-Global Trends in the Competitive, Technological and R&D Landscape” discusses both the pipeline and market shares of monoclonal antibodies (mAbs) across a number of therapy areas. mAbs are defined as a collection of antibodies produced from a single B-cell clone. These antibodies therefore share binding specificity towards a certain antigen, and can be used as a means of targeted therapy within a number of indications across the pharmaceutical market.<\/span><\/p>\n

mAbs have been in development in humans since the mid-1970s, and a substantial number of mAb products have entered the market. However, the majority are still in early-stage development, indicating delays and setbacks in the progression of potential products. Despite this, mAbs are the largest and fastest-growing segment of the biopharmaceutical sector, and account for almost half of the global revenue accrued from this area annually.<\/span><\/p>\n

The pipeline is highly active, with 2,836 mAbs currently in development. Most are at an early stage of development, with 76% at the Discovery or Preclinical stage. Additionally, there are currently 85 mAb programs in Phase III development, and 22 at the Pre-registration stage, accounting for just under 4% of the total mAb pipeline.<\/span><\/p>\n

Get More Information@ <\/strong>http:\/\/www.reportsweb.com\/monoclonal-antibodies-global-trends-in-the-competitive-technological-and-randd-landscape<\/a><\/p>\n

This CBR report provides a comprehensive view of the clinical, R&D, commercial and competitive landscape of mAbs, and assesses key developments in manufacturing and development, covering strategies to combat challenges associated with the use of mAbs in human patients.<\/span><\/p>\n

Table of Contents<\/span>
1 Table of Contents 2<\/span>
1.1 List of Tables 3<\/span>
1.2 List of Figures 3<\/span>
2 Overview of mAbs 4<\/span>
2.1 Initial mAb Development 6<\/span>
2.2 Transition to Therapeutics 6<\/span>
2.3 Present-Day Clinical and Research Applications 7<\/span>
2.4 Commercial Progress within the mAb Market 8<\/span>
3 Manufacture and Mechanism of mAbs 10<\/span>
3.1 Classification of mAbs 10<\/span>
3.1.1 By Type 10<\/span>
3.1.2 By Target Specificity 11<\/span>
3.1.3 By Mechanism of Action 13<\/span>
3.2 Production of mAbs 15<\/span>
3.2.1 Hybridomas 15<\/span>
3.2.2 Phage Libraries\/Phage Display 17<\/span>
3.2.3 Transgenic Animals 18<\/span>
3.3 Challenges in the mAb Market 18<\/span>
3.3.1 Strategies for Improving mAb Efficacy 18<\/span>
3.3.2 Biosimilars and Biobetters 21<\/span>
4 Major mAb-Targeting Therapy Areas 23<\/span>
4.1 Anti-Cancer 23<\/span>
4.2 Anti-Inflammatory\/Autoimmune 25<\/span>
5 Key Marketed mAb Products 27<\/span>
5.1 Humira (adalimumab) and Remicade (infliximab) 27<\/span>
5.2 Rituxan (rituximab) 29<\/span>
5.3 Avastin (bevacizumab) 30<\/span>
5.4 Herceptin (trastuzumab) 32<\/span>
5.5 Opdivo (nivolumab) 33<\/span>
5.6 Lucentis (ranibizumab) 34<\/span>
5.7 Stelara (ustekinumab) 36<\/span>
5.8 Soliris (eculizumab) 37<\/span><\/span><\/p>\n

Get Sample Copy of Report@ <\/strong>http:\/\/www.reportsweb.com\/inquiry&RW00011199424\/sample<\/a><\/p>\n

6 mAb Pipeline 39<\/span>
6.1 mAb Pipeline by Therapy Area and Stage of Development 39<\/span>
6.2 mAb Pipeline by mAb Type 42<\/span>
6.3 Company Positioning 44<\/span>
6.3.1 Companies by Therapy Area 45<\/span>
6.3.2 Companies by Stage of Development 46<\/span>
6.3.3 Companies by mAb Type 47<\/span>
7 Conclusion 48<\/span>
8 Appendix 49<\/span>
8.1 Abbreviations 49<\/span>
8.2 References 50<\/span>
8.3 Report Methodology 57<\/span>
8.4 About GBI Research 57<\/span>
8.5 Disclaimer 57<\/span><\/span><\/p>\n

Buy This Report@ <\/strong>http:\/\/www.reportsweb.com\/buy&RW00011199424\/buy\/2995<\/a><\/p>\n

1.1 List of Tables<\/span>
Table 1: Causes of Immunogenicity and Strategies to Overcome Them 19<\/span>
Table 2: mAb Products within Oncology Market with 2016 Revenue Exceeding $1 Billion 24<\/span>
Table 3: mAb Products within Immunology Market with 2016 Revenue Exceeding $1 Billion 26<\/span>
Table 4: Marketed mAb Products, Humira 27<\/span>
Table 5: Marketed mAb Products, Remicade 28<\/span>
Table 6: Marketed mAb Products, Rituxan 30<\/span>
Table 7: Marketed mAb Products, Avastin 31<\/span>
Table 8: Marketed mAb Products, Herceptin 32<\/span>
Table 9: Marketed mAb Products, Opdivo 34<\/span>
Table 10: Marketed mAb Products, Lucentis 35<\/span>
Table 11: Marketed mAb Products, Stelara 36<\/span>
Table 12: Marketed mAb Products, Soliris 37<\/span><\/span><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> ReportsWeb
Contact Person:<\/strong> Rajat Sahni
Email:<\/strong> sam@reportsweb.com
Phone:<\/strong> +1-646-491-9876
City:<\/strong> Pune
Country:<\/strong> India
Website:<\/strong> http:\/\/www.reportsweb.com\/monoclonal-antibodies-global-trends-in-the-competitive-technological-and-randd-landscape<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Reports Web announces the release of market assessment report on \u201cMonoclonal Antibodies-Global Trends in the Competitive, Technological and R&D Landscape”. The report is segmented into several key Regions, with production, consumption, revenue and market share. GBI Research’s latest report, “Monoclonal … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-157491","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/157491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=157491"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/157491\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=157491"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=157491"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=157491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}